EOLS - NASDAQ
Evolus, Inc.
$6.57
+6.5%Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
At a Glance
Live SnapshotEvolus, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Evolus, Inc. Income Statement
EOLS • NASDAQ
| Evolus, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||
297.2M | 266.3M | 202.1M | 148.6M | 99.7M | 56.5M | 34.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||
(104.4M) | (84M) | (61.6M) | (58.8M) | (43.5M) | (18.3M) | (8M) | (9K) | (218K) | (326K) | (416K) | |
192.8M | 182.3M | 140.5M | 89.8M | 56.1M | 38.2M | 26.9M | -9K | -218K | -326K | -416K | |
OPERATING INCOME | |||||||||||
(230.4M) | (216.7M) | (189.8M) | (155.1M) | (100.5M) | (191.3M) | (125.9M) | (35.6M) | (11.7M) | (20M) | (31M) | |
(220.8M) | (198M) | (164.9M) | (141.8M) | (112.1M) | (98.2M) | (113.6M) | (29.1M) | (4.8M) | (7M) | (9.9M) | |
(9.6M) | (9.2M) | (15.4M) | (6.7M) | (2.1M) | (1.7M) | (4M) | (6.5M) | (6.7M) | (12.6M) | (20.7M) | |
-37.6M | -34.4M | -49.2M | -65.3M | -44.4M | -153.1M | -98.9M | -46.1M | -11.7M | -20M | -31M | |
PRE-TAX INCOME | |||||||||||
(19.7M) | (18.7M) | (13.8M) | (9.1M) | (1.4M) | (10.5M) | (8M) | (863K) | (0.0) | (0.0) | (0.0) | |
-17.8M | -15.5M | -13M | -9M | -1.4M | -9.9M | -6.1M | -660K | 0.0 | 0.0 | 0.0 | |
(0.0) | (9.5M) | (9.4M) | (6.5M) | -13.6M | (91.4M) | (8.3M) | (0.0) | -5K | -6K | -39K | |
-13.4M | -15.3M | -12.3M | -9M | -2.4M | -9.9M | -6.1M | -660K | -5K | -6K | -39K | |
-51M | -49.8M | -61.5M | -74.3M | -46.8M | -162.9M | -105.1M | -46.8M | -11.7M | -20M | -31M | |
NET INCOME | |||||||||||
(677K) | (664K) | (176K) | (95K) | (42K) | (77K) | -15M | (65K) | -7.3M | (93K) | (93K) | |
-51.6M | -50.4M | -61.7M | -74.4M | -46.8M | -163M | -90M | -46.9M | -4.5M | -20.1M | -31.1M |
SEC Filings
EOLS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 13, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 08, 2025 | September 08, 2025 | 2025 |
Related Guides
Continue your EOLS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.